Provention Bio (PRVB) Updates.
LATEST UPDATE July 13th, 2022, below.
(2021) We're getting way too many calls on...
Hapbee (HAPB) Expands Leadership Team to Support Aggressive Growth Strategy
VANCOUVER, BC, Aug. 6, 2021 /CNW/ - Hapbee Technologies, Inc. (TSXV: HAPB) (OTCQB: HAPBF) (FSE: HA1) ("Hapbee" or the "Company"), the leading wearable, wellness technology company has...
Adding Hapbee Tech (HAPB, HAPBF) $0.34 to Biotech Six Pack Watch List.
UPDATE ON BIOTECH SIX PACK, SIX STOCKS WE EXPECT TO DOUBLE.
While the Biotech Stock Review was launched...
Wall Street Showing Love. Hepion Pharma (HEPA), Citius Pharma (CTXR) Raise $166 Million.
Hepion (HEPA) Banked $88 Million Yesterday, Citius (CTXR) Banks $78 Million Today.
We're beginning to believe (and...
Hepion (HEPA) Back in the Spotlight, Gains 230% in May.
Hepion (HEPA) Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and...
Citius Pharma (CTXR) Updates Shareholders.
Citius Update Stem Cell Study
Citius Pharmaceuticals, Inc announced that it will present a poster at the International Society...
Preventing Type I Diabetes. Here’s How Provention (PRVB) Works.
Here's How Provention's Treatment Works.
Interview With an Actual Provention Bio (PRVB) Clinical Trial Participant.
And We Have a $26.4 Billion Winning Trifecta!
THREE PREVIOUS WINNERS*
Immunomedics (IMMU) $3 to $87 up 2,800%, a gain of $20.7 billion. Acquired...
Citius Pharmaceuticals, Inc. (CTXR) Reports Fiscal Full Year 2023 Financial Results and Provides Business...
Mino-Lok® Pivotal Phase 3 trial enrollment completed; topline data expected 2Q 2024
LYMPHIR™ BLA resubmission on track for early 2024
Interview: Scott Donnell from Hapbee (HAPB, HAPBF) on Wall Street Reporter.
Transcript follows.
Hapbee CEO Live with the Wall Street Reporter
Listen in as Hapbee CEO...
Latest article
Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.
Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.
CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...
GeoVax (GOVX) Launches Vaccine Manufacturing System.
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
Manufacturing Process for Phase 3 and Commercial Production...
